Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Accurately reflects atorvastatin’s mechanism via HMG-CoA reductase inhibition and provides label-consistent information for grapefruit juice (CYP3A4 inhibition increasing atorvastatin concentrations). Several interaction claims (pomegranate juice, berries, metabolism slowing, “more studies needed,” and increased risk with calcium channel blockers) are not supported by the provided label excerpts, and one grapefruit-related claim is contradicted by the direction of the interaction described in the label.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower LDL (bad) cholesterol in the blood.
12.1 Mechanism of Action (reduces LDL-C; HMG-CoA reductase inhibition)
Lipitor inhibits the enzyme HMG-CoA reductase to lower LDL cholesterol.
12.1 Mechanism of Action (selective, competitive inhibitor of HMG-CoA reductase)
Grapefruit and certain berries contain compounds that may interact with the enzyme, potentially interfering with Lipitor's efficacy.
7.2 Grapefruit Juice (components inhibit CYP 3A4 and can increase atorvastatin plasma concentrations); no provided support for “certain berries”
Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), have issued warnings about potential interactions between certain medications and grapefruit or its juice.
7.2 Grapefruit Juice (drug interaction warning/statement that grapefruit juice can increase atorvastatin concentrations)
Unsupported Statements
Consuming large amounts of pomegranate juice may reduce the effectiveness of Lipitor by slowing down its metabolism.
No pomegranate juice interaction information is present in the provided label excerpts.
Consuming certain berries may reduce the effectiveness of Lipitor by slowing down its metabolism.
No provided label support for “certain berries” or the specific claimed mechanism/effect.
Research suggests that grapefruit and certain berries may reduce Lipitor's effectiveness by slowing down its metabolism.
The provided label excerpt supports increased atorvastatin concentrations from grapefruit juice, but does not support “reducing effectiveness,” “certain berries,” or “slowing down its metabolism.”
More studies are needed to confirm the magnitude of the interaction and its clinical significance.
No such statement is present in the provided label excerpts.
The risk of interaction may be higher for people taking other medications, such as calcium channel blockers, that are sensitive to the same enzyme.
The provided label excerpt does not mention calcium channel blockers or increased interaction risk for that subgroup.
Contradictions
Low
AI Statement
Eating grapefruit may reduce the effectiveness of Lipitor by slowing down its metabolism.
Label Reference
7.2 Grapefruit Juice (grapefruit juice components inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin; directionality is increased exposure rather than reduced effectiveness via slowed metabolism)
Important Omissions
Label-consistent characterization of the grapefruit juice interaction as CYP 3A4 inhibition leading to increased atorvastatin plasma concentrations (and the noted threshold of excessive consumption >1.2 liters/day).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several interaction claims are not supported by the provided label excerpts (pomegranate/berries and specific “slowing metabolism to reduce effectiveness” framing). One grapefruit claim is contradicted by the label’s described effect direction (increased plasma concentrations via CYP3A4 inhibition).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple food-interaction claims (pomegranate, berries) and mechanistic framing (slowing metabolism to reduce effectiveness) lack support in the provided label excerpts; grapefruit is described with opposite directionality than the label’s statement.
Suggested Improvement
Limit interaction discussion to the provided label-supported grapefruit juice statement (CYP3A4 inhibition and increased atorvastatin plasma concentrations, especially with excessive intake >1.2 L/day) and remove or qualify unsupported claims about pomegranate/berries, metabolism slowing, “more studies needed,” and calcium channel blocker-specific heightened interaction risk.